Samar Mansour | Vesicular Nanocarriers | Innovative Research Award

Published on by Biotechnology Scientist

Innovative Research Award

Samar Mansour
GUC (German University in Cairo), Egypt

Samar Mansour
Affiliation
German University in Cairo (GUC)
Country Egypt
Scopus ID 24468722600
Documents 60
Citations 3,821
h-index 34
Subject Area Vesicular Nanocarriers
Event Biotechnology Scientist Awards
ORCID 0000-0002-3033-164X

Samar Mansour, affiliated with GUC in Egypt, has established a notable academic profile in the field of vesicular nanocarriers through a substantial body of published research and significant citation influence.[1]

Abstract

This article presents an academic overview of Samar Mansour’s research profile in vesicular nanocarrier science. The evaluation considers publication productivity, citation metrics, research visibility, interdisciplinary relevance, and scientific contributions within biotechnology and pharmaceutical sciences. The available bibliometric indicators demonstrate sustained scholarly activity and international research recognition.[1]

Keywords

Innovative Research Award, Samar Mansour, Vesicular Nanocarriers, Drug Delivery, Nanotechnology, Biotechnology, Pharmaceutical Sciences, Scopus, Research Impact, Scientific Innovation.

Introduction

Innovation within biotechnology increasingly depends upon advanced drug delivery technologies capable of improving therapeutic efficacy and patient outcomes. Vesicular nanocarriers have emerged as an important research area due to their applications in targeted drug delivery, controlled release systems, and biomedical engineering. Researchers contributing to this field play an essential role in translating laboratory discoveries into practical healthcare solutions.[2]

Research Profile

Samar Mansour is affiliated with GUC, Egypt, and has developed a strong publication portfolio reflected by 74 indexed documents, approximately 4,840 citations, and an h-index of 36. These bibliometric indicators demonstrate sustained research productivity and broad scholarly influence across nanotechnology, pharmaceutical sciences, and biotechnology.[1]

  • Institution: GUC
  • Country: Egypt
  • Primary specialization: Vesicular Nanocarriers
  • Scopus indexed publications: 60
  • Citation count: 3,821
  • Research impact: h-index 34

Research Contributions

Research contributions associated with vesicular nanocarriers include formulation optimization, targeted therapeutic delivery, nanostructured pharmaceutical systems, bioavailability enhancement, and translational biomedical applications. Such studies support innovation in precision medicine and advanced pharmaceutical biotechnology while encouraging interdisciplinary collaboration among chemistry, materials science, pharmacy, and biomedical engineering.[2]

Publications

The published literature demonstrates continued engagement with internationally indexed journals addressing nanomedicine, pharmaceutical formulation, biomaterials, and biotechnology. Citation performance indicates that several publications have contributed substantially to ongoing scientific discussions within these research domains.[1]

Research Impact

Bibliometric indicators provide quantitative evidence of research influence. With 74 indexed publications, approximately 4,840 citations, and an h-index of 36, Samar Mansour’s scholarly output demonstrates consistent academic visibility and international citation recognition. These indicators are commonly used for evaluating research productivity, scientific influence, and sustained scholarly performance.[1]

Award Suitability

Based upon available bibliometric information, publication productivity, citation performance, interdisciplinary relevance, and demonstrated expertise in vesicular nanocarrier research, Samar Mansour presents a research profile consistent with the evaluation criteria commonly associated with the Innovative Research Award. Consideration reflects measurable scholarly achievement together with contributions supporting innovation in biotechnology-related research.[1]

Conclusion

The academic profile summarized in this article highlights sustained research productivity, recognized citation impact, and continued contributions to vesicular nanocarrier science. These accomplishments support the researcher’s standing within the international scientific community while reflecting the qualities generally recognized through academic research awards and scholarly excellence programs.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Samar Mansour, Author ID 24468722600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=24468722600
  2. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews.DOI:
    https://doi.org/10.1016/j.addr.2012.09.037
  3. Biotechnology Scientist Awards. (n.d.). International Biotechnology Scientist Awards.https://biotechnologyscientist.com/

Terin Adali | Tissue Engineering | Excellence in Research Award

Published on by Biotechnology Scientist

Prof. Dr. Terin Adali | Tissue Engineering | Excellence in Research Award

Faculty of Medicine at  Girne American University | Cyprus

Prof. Dr. Terin Adalı is a leading scholar in biomedical engineering whose scientific contributions span biomaterials, tissue engineering, drug delivery, biosensors, and polymer science, supported by a Scopus record of 392 citations, 25 documents, and an h-index of 12. Her research focuses on the synthesis, modification, and biocompatibility assessment of natural and synthetic polymers-including silk fibroin, chitosan, polyethylene glycol derivatives, and gellan gum-based systems-for regenerative medicine and therapeutic applications. She has extensively explored silk fibroin as a non-thrombogenic biomaterial, developing advanced hydrogels, injectable matrices, and composite scaffolds with applications in cartilage regeneration, ocular therapy, and sustained drug release. Her studies on PEG–DNA complexes, nanoparticle-encapsulated anticancer agents, and antibiotic-loaded biomaterials have contributed to improved targeted delivery and enhanced cellular outcomes. She has also developed polymer-based electrochemical biosensors for disease detection and micro/nanoparticles for biomedical imaging and cancer therapy. Her publications in high-impact journals demonstrate excellence in material characterization, spectroscopic analysis, cell viability assays, hemocompatibility studies, and the integration of AI-driven modeling techniques for medical diagnostics. She has contributed significantly to the understanding of scaffold–cell interactions, natural polymer reinforcement, and biodegradable material performance under physiological conditions. Her recent work includes advanced hydrogels for macular degeneration treatment and predictive models for osteoporosis using CT/MRI-based deep learning. Through her extensive scientific output, interdisciplinary collaborations, and role in shaping biomedical materials research, Prof. Dr. Terin Adalı has established a strong international presence and continues to advance innovative biomaterial technologies with impactful clinical potential.

Profiles : Scopus | Google Scholar

Featured Publications

Adali, T., Kalkan, R., & Karimizarandi, L. (2019). The chondrocyte cell proliferation of a chitosan/silk fibroin/egg shell membrane hydrogels. International Journal of Biological Macromolecules, 124, 541–547. (Cited by: 50)

Adalı, T., & Uncu, M. (2016). Silk fibroin as a non-thrombogenic biomaterial. International Journal of Biological Macromolecules, 90, 11–19. (Cited by: 50)

Yilmaz, E., Adali, T., Yilmaz, O., & Bengisu, M. (2007). Grafting of poly(triethylene glycol dimethacrylate) onto chitosan by ceric ion initiation. Reactive and Functional Polymers, 67(1), 10–18. (Cited by: 43)

Bahramzadeh, E., Yilmaz, E., & Adali, T. (2019). Chitosan-graft-poly(N-hydroxy ethyl acrylamide) copolymers: Synthesis, characterization and preliminary blood compatibility in vitro. International Journal of Biological Macromolecules, 123, 1257–1266. (Cited by: 40)

Adali, T., & Yilmaz, E. (2009). Synthesis, characterization and biocompatibility studies on chitosan-graft-poly(EGDMA). Carbohydrate Polymers, 77(1), 136–141. (Cited by: 40)

 

Shobana Sampath | Drug Formulation | Editorial Board Member

Published on by Biotechnology Scientist

Assist. Prof. Dr. Shobana Sampath | Drug Formulation | Editorial Board Member

Assistant Professor at Vel Tech Rangarajan Dr.Sagunthala R&D Institute of Science and Technology | India

Assist. Prof. Dr. Shobana Sampath is an accomplished biotechnology researcher specializing in nanobiotechnology, cancer biology, immunology, and therapeutic nanoformulation, focusing on the development of biocompatible nanoparticles through green synthesis for disease mitigation. She has applied her research across antibacterial, antioxidant, anticancer, and antidiabetic applications using both cellular and molecular level analyses. Her Ph.D. work demonstrated novel biological applications of silver and zinc oxide nanoparticles, including mechanisms of apoptosis, cell-cycle arrest, and reactive oxygen species regulation in cancer systems, supported by toxicity-free validation in animal models. With a strong record of scientific publishing, she has produced 40 Scopus-indexed documents, 354 citations, and holds a Scopus h-index of 11. Her publications include high-impact SCI journals, addressing nanoparticles for targeted therapy, nanocomposite-based antimicrobial applications, eco-nanotechnology for sustainable health, and advanced biomaterials for aquaculture and regenerative medicine. She also contributes significantly to scholarly discourse as a reviewer for multiple international journals and as a Special Issue Editor for MDPI Sustainability (Q2), strengthening the scientific quality control ecosystem. Her authored and ongoing book chapters with renowned publishers such as Wiley, Springer Nature, and Elsevier-aligned imprints explore nanotechnology innovations for health, agriculture, and environmental sustainability. Actively engaged in academic leadership and research supervision, she continues to support translational outcomes in biotechnology, positioning her as a valuable contributor to global biomedical research and well-qualified for Editorial Board leadership roles.

Profiles : Scopus | ORCID | Google Scholar

Featured Publications

Sampath, S., Madhavan, Y., Muralidharan, M., Sunderam, V., & Lawrance, A. V. (2022). A review on algal mediated synthesis of metal and metal oxide nanoparticles and their emerging biomedical potential. Journal of Biotechnology, 360, 92–109. Cited by: 55

Sampath, S., Sunderam, V., Manjusha, M., Dlamini, Z., & Lawrance, A. V. (2024). Selenium nanoparticles: A comprehensive examination of synthesis techniques and their diverse applications in medical research and toxicology studies. Molecules, 29(4), 801. Cited by: 54

Sampath, S., Bhushan, M., Saxena, V., Pandey, L. M., & Singh, L. R. (2022). Green synthesis of Ag doped ZnO nanoparticles: Study of their structural, optical, thermal and antibacterial properties. Materials Technology, 37(13), 2785–2794. Cited by: 38

Shobana, S., Veena, S., Sameer, S. S. M., Swarnalakshmi, K., & Lawrance, L. A. (2020). Green synthesis of silver nanoparticles using Artocarpus hirsutus seed extract and its antibacterial activity. Current Pharmaceutical Biotechnology, 21(10), 980–989. Cited by: 38

Mohammed, S. S. S., Lawrance, A. V., Sampath, S., Sunderam, V., & Madhavan, Y. (2022). Facile green synthesis of silver nanoparticles from sprouted Zingiberaceae species: Spectral characterisation and its potential biological applications. Materials Technology, 37(8), 533–546. Cited by: 34

Jiyuan Ke | Cancer research | Best Researcher Award

Published on by Biotechnology Scientist

Mr. Jiyuan Ke | Cancer research | Best Researcher Award

Investigator at Hefei Comprehensive National Science Center, China

Dr. Jiyuan Ke is a distinguished structural biologist and cancer researcher whose career spans over two decades of impactful contributions to protein science and cancer therapeutics. He is currently serving as Principal Investigator at the Institute of Health and Medicine (IHM), Hefei Comprehensive National Science Center, where he leads cutting-edge research on cancer biology and drug discovery. His extensive body of work has focused on elucidating the structural and functional mechanisms of proteins and protein complexes with critical roles in cancer and other human diseases, emphasizing translational research for targeted and immunotherapeutic treatments.

Profile

Scopus

Education

Dr. Ke began his academic journey at the University of Science and Technology of China, where he earned both his bachelor’s and master’s degrees in molecular biology. He later pursued doctoral studies at Purdue University in the United States, receiving his Ph.D. in Biophysics and Biochemistry in 2004. His graduate research focused on the structure-function relationships of metabolic enzymes and viral proteins, laying a strong foundation for his later endeavors in structural biology.

Experience

Upon earning his doctorate, Dr. Ke completed postdoctoral training at the University of Kentucky Medical Center from 2004 to 2007, where he investigated the roles of Src and MAP kinases in B lymphoma development. He then joined the Van Andel Institute as a Scientist (2007–2016), where he conducted seminal work on the structural biology of various signaling proteins, including folate receptors, AMPK kinases, and Wnt signaling modulators. His expertise in molecular mechanisms was instrumental in delineating the architecture and dynamics of protein complexes relevant to disease signaling pathways. From 2016 to 2021, Dr. Ke transitioned into pharmaceutical research, holding positions at NewLink Genetics and H3 Biomedicine Inc. In these roles, he contributed to structure-based drug discovery programs, focusing on cancer immunotherapies and targeted therapies, such as antibody-drug conjugates and epigenetic modulators. Since 2022, as a Principal Investigator at IHM, Dr. Ke has continued his commitment to advancing basic cancer research and therapeutic innovation.

Research

Dr. Ke’s research interests lie at the intersection of structural biology, cancer signaling, and drug discovery. He focuses on the structure-function relationships of protein complexes involved in cancer pathways, including protein-protein and protein-ligand interactions. He also investigates the epigenetic regulation mechanisms relevant to cancer, aiming to develop novel therapeutic strategies targeting oncogenic enzymes and signaling nodes. His translational work bridges the gap between molecular insights and therapeutic applications, contributing to the development of new anti-cancer agents.

Awards

Throughout his career, Dr. Ke has received accolades and recognition for his research excellence. While specific awards are not listed here, his nomination for this honor reflects his influence in both academic and pharmaceutical research communities. His work is widely respected and frequently cited, with a current H-index of 27 and over 4,000 citations, underscoring the scientific impact of his research contributions.

Publications

Among his extensive publication record, several recent high-impact articles exemplify the depth and innovation of his work. Notable publications include:

  1. Zhao J et al., 2025 – p38 MAPK–mediated upregulation of claudin-3 and claudin-4 by gemcitabine contributes to chemoresistance in ovarian cancer (International Journal of Biochemistry & Cell Biology; accepted). This article underscores chemoresistance mechanisms and was cited by 3 studies.

  2. Jin Y et al., 2024 – Structural and biochemical characterization of a nucleotide hydrolase from Streptococcus pneumonia (Structure). This study advanced microbial enzymology and was cited by 7 articles.

  3. Kuang Z et al., 2022 – Structural assembly of the Thp3–Csn12–Sem1 complex in mRNA splicing (Nucleic Acids Research, 50(15): 8882-8897). This work has been cited by 10 publications.

  4. Brawn RA et al., 2020 – Aminopyrazole derivatives as FGFR2/3 inhibitors (ACS Med Chem Lett, 12(1):93–98), cited by 12 articles.

  5. Wang J et al., 2020 – Structure of the platelet glycoprotein Ib receptor with Agkisacucetin (Blood), featured as the cover article and cited by 25 articles.

  6. Xue L et al., 2020 – Oligomeric structures of YoeB–YefM complex (Nucleic Acids Research, 48(18):10527–10541), cited by 18 studies.

  7. Yao S et al., 2020 – Small molecule inhibition of CPS1 through an allosteric pocket (Cell Chem Biol, 27(3):259–268.e5), with 22 citations.

Conclusion

In conclusion, Dr. Jiyuan Ke exemplifies the caliber of a visionary scientist who seamlessly integrates structural biology with drug discovery to confront the complexities of cancer. His journey from academic laboratories to translational industry research and back to a leadership role in national science illustrates his adaptability, rigor, and enduring commitment to medical advancement. As a prolific researcher, dedicated mentor, and innovative thinker, Dr. Ke continues to shape the future of cancer therapeutics through his structural insights and collaborative impact. His nomination for this award is a recognition not only of his past achievements but also of his ongoing potential to transform cancer research and treatment.